Epo CERA 50mcg


third-generation molecule, Continuous Erythropoietin Receptor Activator (CERA), incorporating a large polymer chain, has been developed. CERA has an elimination half-life that is considerably longer than the half-life of either epoetin or darbepoetin alfa. CERA may also have different receptor binding characteristics and pharmacology from other erythropoietic agents;  CERA is administered either once every two weeks (to correct anemia) or once per month (to maintain hemoglobin levels). This offers a potential advantage over other erythropoietin-stimulating agents that require more frequent administration. Studies involving erythropoietin-naïve patients found no difference between correcting renal anemia with CERA once every two weeks compared to results with other erythropoietin-stimulating agents that were administered up to three times weekly. Compared to previous erythropoietin-stimulating agents, CERA has a dramatically lengthened half-life, making it the only erythropoietin-stimulating agents licensed for once-a-month dosing.


Pegylated erythropoietin
Equivalent to 40000ui of epo alpha by customers report


There are no reviews yet.

Be the first to review “Epo CERA 50mcg”

Your email address will not be published. Required fields are marked *